CN117106674B - Lactobacillus plantarum OPB15 capable of reducing uric acid and repairing microecological balance of female private parts and application - Google Patents
Lactobacillus plantarum OPB15 capable of reducing uric acid and repairing microecological balance of female private parts and application Download PDFInfo
- Publication number
- CN117106674B CN117106674B CN202311367990.8A CN202311367990A CN117106674B CN 117106674 B CN117106674 B CN 117106674B CN 202311367990 A CN202311367990 A CN 202311367990A CN 117106674 B CN117106674 B CN 117106674B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- opb15
- uric acid
- mice
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 85
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 85
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 85
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 63
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 61
- 229940116269 uric acid Drugs 0.000 title claims abstract description 61
- 230000001603 reducing effect Effects 0.000 title claims abstract description 30
- 241000699670 Mus sp. Species 0.000 claims abstract description 47
- 239000003814 drug Substances 0.000 claims abstract description 16
- 241000186660 Lactobacillus Species 0.000 claims abstract description 15
- 230000009286 beneficial effect Effects 0.000 claims abstract description 10
- 238000009629 microbiological culture Methods 0.000 claims abstract description 7
- 238000004321 preservation Methods 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 42
- 201000001431 Hyperuricemia Diseases 0.000 claims description 30
- 238000000855 fermentation Methods 0.000 claims description 27
- 230000004151 fermentation Effects 0.000 claims description 27
- 229940109239 creatinine Drugs 0.000 claims description 21
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims description 18
- 210000001072 colon Anatomy 0.000 claims description 17
- 210000002966 serum Anatomy 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 16
- 210000001519 tissue Anatomy 0.000 claims description 15
- 108090001005 Interleukin-6 Proteins 0.000 claims description 14
- 108090001007 Interleukin-8 Proteins 0.000 claims description 14
- 241000588724 Escherichia coli Species 0.000 claims description 11
- 244000052616 bacterial pathogen Species 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 10
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 9
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 9
- 210000003756 cervix mucus Anatomy 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 239000002537 cosmetic Substances 0.000 claims description 8
- 210000002700 urine Anatomy 0.000 claims description 8
- 241000191940 Staphylococcus Species 0.000 claims description 7
- 210000002175 goblet cell Anatomy 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 230000006870 function Effects 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000000645 desinfectant Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000029142 excretion Effects 0.000 claims description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 229940069328 povidone Drugs 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- OKODKVMXHLUQSW-JITBQSAISA-M sodium;(e)-4-hydroxy-4-oxobut-2-enoate;octadecanoic acid Chemical compound [Na+].OC(=O)\C=C\C([O-])=O.CCCCCCCCCCCCCCCCCC(O)=O OKODKVMXHLUQSW-JITBQSAISA-M 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 12
- 229940039696 lactobacillus Drugs 0.000 abstract description 11
- 230000002496 gastric effect Effects 0.000 abstract description 9
- 244000005700 microbiome Species 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 6
- 230000004083 survival effect Effects 0.000 abstract description 5
- 230000000813 microbial effect Effects 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 28
- 241000894006 Bacteria Species 0.000 description 19
- 239000000243 solution Substances 0.000 description 17
- 230000000968 intestinal effect Effects 0.000 description 16
- 102000004889 Interleukin-6 Human genes 0.000 description 13
- 210000001215 vagina Anatomy 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000013641 positive control Substances 0.000 description 10
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 239000006041 probiotic Substances 0.000 description 8
- 235000018291 probiotics Nutrition 0.000 description 8
- 238000001179 sorption measurement Methods 0.000 description 8
- 102000004890 Interleukin-8 Human genes 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000012258 culturing Methods 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 201000005569 Gout Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- QARYADFHOUHDSW-UHFFFAOYSA-M potassium 2H-oxazine-3-carboxylate Chemical compound O1NC(=CC=C1)C(=O)[O-].[K+] QARYADFHOUHDSW-UHFFFAOYSA-M 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- -1 tribromone Chemical compound 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- XINCECQTMHSORG-UHFFFAOYSA-N Isoamyl isovalerate Chemical compound CC(C)CCOC(=O)CC(C)C XINCECQTMHSORG-UHFFFAOYSA-N 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000222640 Polyporus Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241001501882 Rhodomonas Species 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 208000037009 Vaginitis bacterial Diseases 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000004953 colonic tissue Anatomy 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Reproductive Health (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
Abstract
The invention belongs to the technical field of microorganisms, and discloses lactobacillus plantarum OPB15 capable of reducing uric acid in mice and repairing microecological balance at female private parts, which is named as follows: OPB15, class name: lactobacillus plantarum (Lactobacillus), accession number: cgmccno.27735, date of preservation: 2023, 6, 29, deposit unit: china general microbiological culture Collection center, north Chen Xi Lu No.1, 3, the Korean region of Beijing, and the China general microbiological culture Collection center. The lactobacillus plantarum OPB15 disclosed by the invention can resist the gastrointestinal environment, improve the survival rate of the gastrointestinal tract, is beneficial to the field planting of strains, and can be used for preparing functional microbial agents, foods and medicines for reducing uric acid and repairing microecological balance of female private parts.
Description
Technical Field
The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus plantarum OPB15 capable of reducing uric acid and repairing microecological balance of female private parts and application thereof.
Background
Hyperuricemia refers to metabolic diseases caused by purine metabolic disturbance and Uric Acid (UA) levels higher than normal. In 2021, the medical guideline of combining hyperuricemia and gout symptoms is provided that the fasting blood uric acid concentration of two times in a normal purine diet state is more than 420 mu mol/L, namely the hyperuricemia is considered. The proportion of people suffering from hyperuricemia in coastal areas is statistically high. Hyperuricemia occurs mainly due to increased uric acid or decreased uric acid excretion in humans, about 2/3 of the urate excreted from the kidneys, and 1/3 of the urate excreted from the intestinal tract, and the micro-ecosystem constituted by the intestinal flora has been considered as a new target for the treatment of hyperuricemia. Creatinine (Cr) and urea nitrogen (BUN) are important indicators of kidney function, with kidney damage accompanied by an increase in urea nitrogen and serum creatinine. At present, the treatment of hyperuricemia mainly depends on drug treatment, such as allopurinol, febuxostat, tribromone, probenecid and the like, but the toxic and side effects of kidneys, gastrointestinal tracts and the like are large, so that the research of intestinal flora has important significance.
Intestinal flora is associated with hyperuricemia. The rising blood uric acid can reversely induce the chronic inflammation of the organism and the intestinal canal and change the environment in the intestinal canal, thereby affecting the distribution of the flora and the change of the quantity and aggravating the hyperuricemia symptom of the organism. Shao et al analyzed 26 stool samples from patients with gout and healthy people by nuclear magnetic resonance hydrogen spectrometry and high throughput sequencing technology, found that the diversity of stool flora of patients with gout was significantly reduced, while the abundance of pathogenic bacterial flora of Bacteroides, rhodomonas and anaerobic rope bacteriaceae was significantly increased. In addition, as early as 1952, buzard et al have first shown by in vitro bacteriostasis experiments that intestinal bacteria have a decomposing effect on uric acid. In the activity research of lactobacillus plantarum ZXH-1304S for degrading creatinine and uric acid (in 2019 of food industry technology), the content of creatinine and uric acid in a Wistar rat can be remarkably reduced. Chinese patent publication No.: CN115287240a, publication date: the lactobacillus plantarum with hyperuricemia and gout preventing and treating effects and application thereof are disclosed in 11.2022 and 4.A long-term gastric lavage of a hyperuricemia model mouse is mainly adopted, and the lactobacillus plantarum LTJ48 can obviously reduce serum uric acid level, has obvious uric acid reducing effect and has kidney protecting effect on the hyperuricemia model mouse. Chinese patent publication No.: CN115287239a, publication date: 2022, 11 and 4 days, discloses lactobacillus plantarum with in-vitro nucleoside and purine degradation capability and uric acid degradation capability and application thereof, and lactobacillus plantarum LTJ1 has excellent in-vitro nucleoside and purine degradation capability and can reduce uric acid level at a cell level. There is growing evidence that the intestinal flora is not only associated with the occurrence of hyperuricemia but also with the therapeutic effects of hyperuricemia.
Modern females are in unreasonable diet due to the continuous increase of life pressure, the in-vivo micro-ecological system disorder caused by the sanitary condition and the change of hormone level, the lactobacillus is reduced, the number of pathogenic bacteria such as escherichia coli, staphylococcus and the like is increased, the flora balance of the vagina is broken, and the infection is caused. Causing various diseases such as bacterial vaginitis, vulvovaginal candidiasis, aerobical vaginosis, etc. A large number of researches show that after bacterial infection, endothelial cells, macrophages, neutrophils and the like can be activated, and a large amount of inflammatory factors such as IL-6, IL-8 and TNF-alpha are released, so that the organism is damaged and destroyed. At present, the commercial private nursing products are usually added with traditional Chinese medicine extracts, antibiotics and other chemical bactericides, and the products have high sterilization rate, can kill a large number of female vaginal pathogenic bacteria groups in a short period, but kill the vaginal resident bacteria and the probiotic bacteria groups at the same time of killing the pathogenic bacteria, destroy the microecological balance of the private parts and even reduce the resistance to the pathogenic bacteria. Thus, microbiological therapy is of great significance to the health of the female private parts.
Chinese patent publication No.: CN104721668A, publication date: the utility model discloses a private care solution for 24 days of 6 months of 2015, which comprises the following substances: polyporus, rhizoma Atractylodis, radix Stemonae, fructus Cnidii, rhizoma Smilacis Glabrae, radix Sophorae Flavescentis, corni fructus, flos Chrysanthemi, pericarpium Granati, alumen, apple essence, and benzoic acid. Through detection, the private care solution has strong killing capacity on diplococcus gonorrhoeae, staphylococcus aureus, escherichia coli and herpes virus, but beneficial lactobacillus is also killed, so that the private care solution is unfavorable for the balance of the whole environment of the private part and damages the whole resistance of the private part. Chinese patent publication No.: CN112675219a, publication date: a composition for repairing microecological balance of female private parts, a preparation method and application thereof are disclosed in 6 th and 24 th 2015. The composition is prepared by simply collocating gallnut, fructus cnidii, cortex moutan and bitter lactobacillus plantarum ATCC8014 fermentation products, and is used for carrying out entity detection on 51 females and detecting flora concentration, flora diversity and dominant strains, but is rough. Chinese patent publication No.: CN115137758A, publication date: 2022, 10 and 4 days, discloses preparation and application of probiotics beneficial to female genital tract health. Providing lactobacillus plantarum CGMCC NO.16871 mycelium, can reduce the content of pro-inflammatory factors IL-4, IL-1 beta and TNF-alpha, and reduce inflammatory injury, thereby playing a role in resisting diseases and maintaining the healthy environment of vagina. Because of the mycelium, a gel preparation is provided, and no cleaning liquid is provided. Meanwhile, the bacteriostasis of escherichia coli and staphylococcus is measured by adopting an oxford plate method, a definite value cannot be obtained, and the difference between the external operation and the actual situation of the actual vaginal environment is large. Meanwhile, the strain has no report of reducing uric acid.
Therefore, the product which has strong sterilization capability and can restore the microecological balance of the private parts of women is very significant.
The invention mainly adopts a single strain, namely lactobacillus plantarum OPB15, can reduce uric acid of mice, and meanwhile, the supernatant fluid is a lactobacillus plantarum OPB15 fermentation product which is used as a washing liquid, so that microecological balance of female private parts can be restored. The lactobacillus plantarum OPB15 is obtained by first independent separation in the laboratory and is preserved in the common microorganism center of China Committee for culture Collection of microorganisms, and related patent publications for regulating intestinal flora, reducing uric acid and simultaneously repairing microecological balance of female private parts of mice with hyperuricemia are not available in the lactobacillus plantarum OPB 15.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide lactobacillus plantarum OPB15 capable of reducing uric acid and repairing microecological balance of female private parts and application thereof.
The technical scheme adopted for solving the technical problems is as follows:
lactobacillus plantarum OPB15 capable of reducing uric acid of mice and repairing microecological balance of female private parts is named as: OPB15, class name: lactobacillus plantarum (Lactobacillus plantarum), accession number: CGMCC No.27735, date of preservation: 2023, 6, 29, deposit unit: china general microbiological culture Collection center (CGMCC) of the China Committee for culture Collection of microorganisms, beijing, chaoyang area, north Chenxi Lu No.1, 3.
Further, the lactobacillus plantarum OPB15 has the following biological properties:
(1) Characteristics of the cells: gram-positive rod-shaped bacteria, non-spore-forming, non-motile bacteria;
(2) Colony characteristics: the diameter is 1.0-1.2 mm, the front surface is round, the center is convex, the edge is neat, the surface is moist and smooth, the transparent and slightly sour;
(3) Growth characteristics: culturing in MRS culture medium at 37deg.C for 12 hr to end of logarithm;
(4) Has strong tolerance to simulated gastrointestinal fluid.
Furthermore, the lactobacillus plantarum OPB15 has the functions of reducing uric acid and repairing microecological balance of female private parts.
The application of the lactobacillus plantarum OPB15 in preparing common foods and/or special functional foods and/or health-care foods and/or cosmetics and/or medical instruments and/or disinfectants and/or medicines capable of reducing uric acid and repairing microecological balance of female private parts.
Further, the general food, the special functional food, the health food, the medicine, the cosmetic, the medical instrument and the disinfection product have at least one of the following functions:
reducing uric acid level of mice with hyperuricemia, in particular reducing Uric Acid (UA), creatinine (Cr) and urea nitrogen (BUN) level in serum of the mice, and increasing creatinine (Cr) and urea nitrogen (BUN) excretions in urine;
or, reduce hyperuricemia mice uric acid level, recover the length of colon villus of the mice, and improve colon tissue morphology;
or, reducing uric acid level in hyperuricemia mice, restoring damaged colon tissue, and increasing goblet cell number;
or restoring the microecological balance of the private part by the fermentation product, specifically increasing the number of beneficial bacteria lactobacillus and reducing the number of pathogenic bacteria escherichia coli and staphylococcus;
or, the fermentation product restores the microecological balance of the private part, in particular to reduce the IL-6, IL-8 and TNF-alpha levels in the vaginal secretion of the mice.
Further, the lactobacillus plantarum OPB15 is a live strain, a strain metabolite or an inactivated strain.
Further, the medicament or cosmetic further comprises a pharmaceutically acceptable carrier, the pharmaceutically acceptable carrier comprising: one or more of a filler, diluent, binder, disintegrant, and lubricant.
Further, the filler is one or more of microcrystalline cellulose, lactose, mannitol, starch or dextrin; the diluent is one or two of ethanol and glycerol; the disintegrating agent is one or more of sodium carboxymethyl starch, crosslinked povidone or low-substituted hydroxypropyl cellulose; the adhesive is one or more of starch paste, syrup, maltose, refined honey or liquid glucose; the lubricant is one or more of magnesium stearate, sodium stearate fumarate, talcum powder or silicon dioxide.
The application of the lactobacillus plantarum OPB15 in preparing fermented foods, metazoan and enzymes is provided.
Further, the application comprises using lactobacillus plantarum OPB15 as a fermenting microorganism to perform fermentation by using food raw materials.
The invention has the advantages and positive effects that:
1. the lactobacillus plantarum OPB15 disclosed by the invention can resist the gastrointestinal environment, improve the survival rate of the gastrointestinal tract, is beneficial to the field planting of strains, and can be used for preparing functional microbial agents, foods and medicines for reducing uric acid and repairing microecological balance of female private parts.
2. The lactobacillus plantarum OPB15 can restore the villus length and improve the intestinal gland arrangement; restoring damaged colon tissue, increasing goblet cell number, and effectively improving intestinal flora structure.
3. The lactobacillus plantarum OPB15 can obviously reduce the levels of Uric Acid (UA), creatinine (Cr) and urea nitrogen (BUN) in serum and increase the excretion amount of creatinine (Cr) and urea nitrogen (BUN) in urine.
4. The lactobacillus plantarum OPB15 fermentation product increases the number of beneficial bacteria lactobacillus and reduces the number of pathogenic bacteria escherichia coli and staphylococcus; the fermentation product can reduce the IL-6, IL-8 and TNF-alpha levels in the vaginal secretion of mice; restoring the microecological balance of the private parts, and has wide application prospect.
Drawings
FIG. 1 is a colony morphology of Lactobacillus plantarum OPB15 according to the invention;
FIG. 2 is a microscopic photograph of Lactobacillus plantarum OPB15 according to the invention;
FIG. 3 is a graph of BLAST results versus tree for the genomic sequence of Lactobacillus plantarum OPB15 of the invention;
FIG. 4 is a graph showing H & E staining of hyperuricemia mice colon tissue by Lactobacillus plantarum OPB15 according to the invention;
FIG. 5 is a graph showing the staining of colon tissue AB-PAS of hyperuricemia mice with Lactobacillus plantarum OPB15 according to the invention.
Lactobacillus plantarum OPB15 capable of reducing uric acid of mice and repairing microecological balance of female private parts is named as: OPB15, class name: lactobacillus plantarum (Lactobacillus plantarum), accession number: CGMCC No.27735, date of preservation: 2023, 6, 29, deposit unit: china general microbiological culture Collection center (CGMCC) of the China Committee for culture Collection of microorganisms, beijing, chaoyang area, north Chenxi Lu No.1, 3.
Detailed Description
The invention will now be further illustrated by reference to the following examples, which are intended to be illustrative, not limiting, and are not intended to limit the scope of the invention.
The various experimental operations involved in the specific embodiments are conventional in the art, and are not specifically noted herein, and may be implemented by those skilled in the art with reference to various general specifications, technical literature or related specifications, manuals, etc. before the filing date of the present invention.
Lactobacillus plantarum OPB15 capable of reducing uric acid of mice and repairing microecological balance of female private parts is named as: OPB15, class name: lactobacillus plantarum (Lactobacillus plantarum), accession number: CGMCC No.27735, date of preservation: 2023, 6, 29, deposit unit: china general microbiological culture Collection center (CGMCC) of the China Committee for culture Collection of microorganisms, beijing, chaoyang area, north Chenxi Lu No.1, 3.
Preferably, the lactobacillus plantarum OPB15 has the following biological properties:
(1) Characteristics of the cells: gram-positive rod-shaped bacteria, non-spore-forming, non-motile bacteria;
(2) Colony characteristics: the diameter is 1.0-1.2 mm, the front surface is round, the center is convex, the edge is neat, the surface is moist and smooth, the transparent and slightly sour;
(3) Growth characteristics: culturing in MRS culture medium at 37deg.C for 12 hr to end of logarithm;
(4) Has strong tolerance to simulated gastrointestinal fluid.
Preferably, the lactobacillus plantarum OPB15 has the functions of reducing uric acid and repairing microecological balance of female private parts.
The application of the lactobacillus plantarum OPB15 in preparing common foods and/or special functional foods and/or health-care foods and/or cosmetics and/or medical instruments and/or disinfectants and/or medicines capable of reducing uric acid and repairing microecological balance of female private parts.
Preferably, the common food, special functional food, health food, medicine, cosmetic, medical instrument, and disinfectant has at least one of the following functions:
reducing uric acid level of mice with hyperuricemia, in particular reducing Uric Acid (UA), creatinine (Cr) and urea nitrogen (BUN) level in serum of the mice, and increasing creatinine (Cr) and urea nitrogen (BUN) excretions in urine;
or, reduce hyperuricemia mice uric acid level, recover the length of colon villus of the mice, and improve colon tissue morphology;
or, reducing uric acid level in hyperuricemia mice, restoring damaged colon tissue, and increasing goblet cell number;
or restoring the microecological balance of the private part by the fermentation product, specifically increasing the number of beneficial bacteria lactobacillus and reducing the number of pathogenic bacteria escherichia coli and staphylococcus;
or, the fermentation product restores the microecological balance of the private part, in particular to reduce the IL-6, IL-8 and TNF-alpha levels in the vaginal secretion of the mice.
Preferably, the lactobacillus plantarum OPB15 is a live strain, a strain metabolite or an inactivated strain.
Preferably, the medicament or cosmetic further comprises a pharmaceutically acceptable carrier, the pharmaceutically acceptable carrier comprising: one or more of a filler, diluent, binder, disintegrant, and lubricant.
Preferably, the filler is one or more of microcrystalline cellulose, lactose, mannitol, starch or dextrin; the diluent is one or two of ethanol and glycerol; the disintegrating agent is one or more of sodium carboxymethyl starch, crosslinked povidone or low-substituted hydroxypropyl cellulose; the adhesive is one or more of starch paste, syrup, maltose, refined honey or liquid glucose; the lubricant is one or more of magnesium stearate, sodium stearate fumarate, talcum powder or silicon dioxide.
The application of the lactobacillus plantarum OPB15 in preparing fermented foods, metazoan and enzymes is provided.
Preferably, the use comprises fermenting the food material with lactobacillus plantarum OPB15 as a fermenting microorganism.
Specifically, the related preparation and detection are as follows:
example 1: screening of Lactobacillus plantarum OPB15
Isolation and screening of Lactobacillus
(1) 0.1mL of yogurt sample (from the automatic brewing yogurt in the home of the herdsman in Kaisha, sinkiang) was inoculated into skim milk medium, and incubated in a constant temperature incubator at 37℃for 48 hours. A small amount of bacterial liquid is picked by an inoculating loop, streaked and inoculated in an MRS agar culture medium plate.
(2) After 48 hours, different colonies are picked up by an inoculating loop according to the shape, size, color and the like of the colonies, and streaked separation and purification are carried out.
(3) Gram-positive bacteria and catalase-negative bacteria were retained by gram staining and catalase analysis.
(4) Obtaining thallus and colony characteristics of the final strain: gram-positive rod-shaped bacteria, non-sporulating, non-motile bacteria (fig. 1); the diameter is about 1.0-1.2 mm, the front face is round, the center is convex, the edge is neat, the surface is moist and smooth, the surface is opaque and has slightly sour taste (figure 2).
Molecular biological identification of Lactobacillus
(1) Single genome extraction
(A) Culturing the screened lactobacillus overnight;
(B) Using a Soxhaust bacteria genome DNA extraction kit, the product number is 1600, taking 1mL of the bacterial suspension cultured overnight, centrifuging in a 1.5mL centrifuge tube at 12000r/min for 1min, and sucking out the supernatant as much as possible;
(C) Adding 200 mu L of lysozyme with a final concentration of 20mg/mL into the thalli, and treating for 40min at 37 ℃;
(D) Adding solution A (10 mmol/L, pH =8.0 Tris-HCl and 1mmol/L EDTA mixed solution, SDS with concentration of 0.08g/mL and NaCl with concentration of 1.5 mol/L) into the mixed solution obtained in the step (C), blowing by a pipette to fully suspend the thalli, adding 20 mu L rNaseA (10 mg/mL) into the suspension, fully reversing and uniformly mixing, and standing at room temperature for 30min;
(E) Adding 20 mu L of proteinase K into the tube, fully and uniformly mixing, and digesting at 55 ℃ for 60min; inverting the centrifuge tube for several times during digestion until the sample is clear and viscous, and proving that the sample is completely digested;
(F) Adding 200 μl of solution B (mixed solution of phenol: chloroform: isoamyl alcohol=25:24:1) into the tube, mixing, and standing at 75deg.C for 15-30 min until the precipitate disappears;
(E) Adding 200 μl of absolute ethanol into the tube, mixing thoroughly, wherein flocculent precipitate may appear without affecting DNA extraction, adding the solution and flocculent precipitate into adsorption column, and standing for 2min;
(F) Centrifuging at 12000rpm for 2min, discarding the waste liquid, and placing the adsorption column into a collecting pipe;
(G) Adding 600 μl of rinse solution (75% ethanol) into the adsorption column, centrifuging at 12000rpm for 1min, discarding the waste liquid, placing the adsorption column into a collecting tube, and repeating for one time;
(H) Centrifuging at 12000rpm for 2min, and placing the adsorption column in a 50 deg.C incubator for several minutes;
(I) Placing the adsorption column into a sterilized 1.5mL centrifuge tube, suspending and dripping 100 μL of the washing liquid (general purpose) preheated by a 65 ℃ water bath into the center of the adsorption film, standing for 5min at room temperature, and centrifuging for 1min at 12000 rpm;
(J) And adding the eluent obtained by centrifugation into an adsorption column, standing for 2min at room temperature, and centrifuging for 2min at 12000rpm to obtain the genome DNA of the lactobacillus.
The 16S rDNA gene sequence of the lactobacillus is as follows:
TTAGGCGGCTGGTTCCTAAAAGGTTACCCCACCGACTTTGGGTGTTACAAACTCTCATGGTGTGACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCGGCATGCTGATCCGCGATTACTAGCGATTCCGACTTCATGTAGGCGAGTTGCAGCCTACAATCCGAACTGAGAATGGCTTTAAGAGATTAGCTTACTCTCGCGAGTTCGCAACTCGTTGTACCATCCATTGTAGCACGTGTGTAGCCCAGGTCATAAGGGGCATGATGATTTGACGTCATCCCCACCTTCCTCCGGTTTGTCACCGGCAGTCTCACCAGAGTGCCCAACTTAATGCTGGCAACTGATAATAAGGGTTGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAACCATGCACCACCTGTATCCATGTCCCCGAAGGGAACGTCTAATCTCTTAGATTTGCATAGTATGTCAAGACCTGGTAAGGTTCTTCGCGTAGCTTCGAATTAAACCACATGCTCCACCGCTTGTGCGGGCCCCCGTCAATTCCTTTGAGTTTCAGCCTTGCGGCCGTACTCCCCAGGCGGAATGCTTAATGCGTTAGCTGCAGCACTGAAGGGCGGAAACCCTCCAACACTTAGCATTCATCGTTTACGGTATGGACTACCAGGGTATCTAATCCTGTTTGCTACCCATACTTTCGAGCCTCAGCGTCAGTTACAGACCAGACAGCCGCCTTCGCCACTGGTGTTCTTCCATATATCTACGCATTTCACCGCTACACATGGAGTTCCACTGTCCTCTTCTGCACTCAAGTTTCCCAGTTTCCGATGCACTTCTTCGGTTGAGCCGAAAGCTTTCACATCAGACTTAAAAAACCGCCTGCGCTCGCTTTACGCCCAATAAATCCGGACAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCACGTAGTAGCCGTGGCTTTCTGGTAATACCGTCATACCTGAACAGTTACTCTCAGATATGTTCTTCTTTAACAACNGAGTTTTACGAGCCGAAACCCTTCTCACTGCTATACATGCAAGTCGAACGAACTCTGGTATTGATTGGTGCTTGCATCATGATTTACATTTCGAGTGAGTGGCGAACTGGTGAGTAACACGTGGGAAACCTGCCCAGAAGCGGGGGATAACACCTGGAAACAGATGCTAATACCGCATAACAACTTGGACCGCATGGTCCGAGTTTGAAAGATGGCTTCGGCTATCACTTTTGGATGGTCCCGCGGCGTATTAGCTAGATGGTGGGGTAACGGCTCACCATGGCAATGATACGTAGCCGACCTGAGAGGGTAATCGGCCACATTGGGACTGAGACACGGCCCAAACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGACGAAAGTCTGATGGAGCAACGCCGCGTGAGTGAAGAAGGGTTTCGGCTCGTAAAACTCTGTTGTTAAAGAAGAACATATCTGAGAGTAACTGTTCAGGTATTGACGGTATTTAACCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTGTCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCGGTTTTTTAAGTCTGATGTGAAAGCCTTCGGCTCAACCGAAGAAGTGCATCGGAAACTGGGAAACTTGAGTGCAGAAGAGGACAGTGGAACTCCATGTGTAGCGGTGAAATGCGTAGATATATGGAAGAACACCAGTGGCGAAGGCGGCTGTCTGGTCTGTAACTGACGCTGAGGCTCGAAAGTATGGGTAGCAAACAGGATTAGATACCCTGGTAGTCCATACCGTAAACGATGAATGCTAAGTGTTGGAGGGTTTCCGCCCTTCAGTGCTGCAGCTAACGCATTAAGCATTCCGCCTGGGGAGTACGGCCGCAAGGCTGAACTCAAGGAATTGACGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCTACGCGAAGACCTTACCNNTCTGACATACTATGCAAATCTAGAGAT。
（2）16S r DNA PCR
bacterial 16S r DNA 50. Mu. LPCR reaction System: 24 mu L of Taq enzyme; dd H 2 O: 18. Mu.L; 27F, 2. Mu.L; 1492R, 2. Mu.L; and (3) a template: 4. Mu.L.
PCR conditions: 94℃for 5min (i.e.step 1); 94℃for 30s (i.e.step 2); 55℃for 30s (i.e.step 3); 30s at 72 ℃ (i.e. step 4); step2 to step4 (30×); and at 72℃for 5min.
Preparing 1% agarose gel, mixing the PCR product with 10000×loading buffer, loading 2 μl, running at 120V for 30min, and performing gel imaging;
the obtained PCR product was sent to a professional sequencing company, and the obtained sequencing result was subjected to searching and similarity alignment in Gen Bank using BLAST (see FIG. 3), and identified as a strain of Lactobacillus plantarum, and stored at-80 ℃.
Example 2: lactobacillus plantarum OPB15 has good tolerance to simulated gastrointestinal fluids
In vitro simulated gastric fluid: the pH value of the 0.1mol/L potassium phosphate buffer solution is regulated to 2.5, pepsin (10 g/L) is added, and the mixture is uniformly mixed and then passes through a 0.22 mu m sterile film, so that simulated gastric juice can be obtained.
In vitro simulated intestinal juice: the pH value of the 0.1mol/L potassium phosphate buffer solution is regulated to 6.8, pancreatin (10 g/L) and pig bile salt (3 g/L) are added, and the mixture is uniformly mixed and then passes through a 0.22 mu m sterile film, thus obtaining the simulated intestinal juice.
Gastric digestion was simulated:
centrifuging culture solution of 3.0 mL Lactobacillus plantarum OPB15 for 3min, collecting mycelium, and placing in simulated gastric juice environment with pH value of 2.5 and 3.0 mL, and simulating gastric juice digestion under anaerobic condition of 37deg.C and 90 r/min. Samples were taken at 0, 1.0, 2.0, 3.0 and h, viable bacteria were counted using a dilution-coated plate count method, and survival rates were calculated.
Intestinal digestion was simulated:
centrifuging culture solution of Lactobacillus plantarum OPB15 at 3.0 mL for 3min, collecting mycelium, and placing in simulated intestinal juice environment with pH value of 6.8 at mL and 37 deg.C under anaerobic condition of 120 r/min for simulating intestinal juice digestion. Samples were taken at 0, 2.0, 4.0, 6.0, 8.0 and h, viable bacteria were counted using a dilution-coated plate count method, and survival rates were calculated.
The survival rate (%) was calculated as the ratio of the number of viable bacteria at the time of sampling to the number of viable bacteria at the time of 0h in the culture solution, expressed as%. The experimental results are shown in table 1 and table 2, and the results show that lactobacillus plantarum OPB15 has better tolerance to artificial simulated gastrointestinal fluids.
Example 3: preparation of lactobacillus plantarum OPB15 fermentation product
(1) Inoculating Lactobacillus plantarum OPB15 stored at 4 ℃ into MRS liquid culture medium for activation, culturing at 36 ℃ for 18h, and activating for 2 times; inoculating the activated strain into MRS liquid test tube culture medium, and culturing at 36 deg.C for 18 hr to obtain seed solution;
(2) Inoculating the seed solution into a fermentation tank according to the inoculation amount of 5% (V/V), controlling the fermentation temperature to 36 ℃, controlling the pH value to 6.0, and fermenting for 48 hours to obtain fermentation liquor;
(3) And (3) centrifuging the fermentation liquor, separating supernatant from sediment, wherein the supernatant is lactobacillus plantarum fermentation product, and centrifuging at 12000rpm for 25min. Sodium alginate, chitosan and sodium hyaluronate with mass percentages of 0.5% and 3.5% are respectively added as protective agents. Crushing the liquid by a high-pressure crusher, setting the temperature to be 4 ℃ and the crushing pressure to be 150MPa, thus obtaining the fermentation product of the lactobacillus plantarum OPB 15.
Example 4: effects of each experimental group on hyperuricemia mice Uric Acid (UA), creatinine (Cr), and urea nitrogen (BUN).
40 SPF-class Balb/c mice are bred in the environment of the light irradiation time of 12 h/12 h, wherein the male body mass is 18-20 g, the temperature is 20-25 ℃, the relative humidity is 50+/-5%. The cells were randomly divided into 4 groups of 10 cells, and the cells were designated as a normal group (i.e., a blank control group), a model group, a positive control group and an experimental group (i.e., a Lactobacillus plantarum group). (1) Blank control group: normal feed feeding is given, and the menstruum is separately irrigated; (2) model group: potassium oxazinate (250 mg/kg, vehicle 5% CMC-Na by mass); (3) positive control group: potassium oxazinate (250 mg/kg, vehicle 5% CMC-Na aqueous solution by mass) +allopurinol (5 mg/kg); (4) experimental group (i.e. lactobacillus plantarum group): potassium oxazinate (250 mg/kg, solvent mass)Concentration 5% CMC-Na aqueous solution) +Lactobacillus plantarum group (1.8X10) 10 CFU/kg); the other groups were dosed by gavage as described above except for the blank group, which was given an equal volume of vehicle (i.e. 5% cmc-Na in water by mass). All groups were fed 14d continuously, 1 time per day, with a gavage volume of 0.3mL/100 g. After 14 days, fasting for 12 hours, taking blood from eyeballs, centrifuging for 20 minutes at a rotating speed of 3000r/min, and separating serum; urine 24 h was collected from the squirrel cage, urine data was recorded, and Uric Acid (UA), creatinine (Cr) and urea nitrogen (BUN) levels in serum were determined using a commercially available kit.
As shown in table 3, the level of UA, BUN, cr in serum of each group was compared, and after the mice of the model group were perfused with potassium oxyzinate, the UA level was significantly higher than that of the normal group (P < 0.05), indicating that the model of hyperuricemia mice was successfully modeled.
After the treatment by lactobacillus plantarum 14d, the uric acid level in the serum of the probiotic experimental group is obviously reduced (P < 0.05) compared with that of the model group, and meanwhile, the uric acid level of the serum of the mice of the probiotic group is close to that of the mice of the positive group. It can also be seen from the data that the urine output from the experimental group also exhibited higher levels, approaching normal group levels. Compared with the model group, the serum creatinine and urea nitrogen levels are obviously reduced (P < 0.05), the improvement effect of the probiotics group on the serum urea nitrogen level is slightly lower than that of the positive group, the serum creatinine level is reduced from 1.03 mu mol/L to 0.66 mu mol/L, the improvement amplitude is nearly doubled, and the effect is obvious (P < 0.05). The change of urea nitrogen and creatinine shows that probiotics have a certain protective effect on kidneys. While the level of creatinine excreted in the urine was 37.22 mmol/L, close to normal.
Example 5: effect of Lactobacillus plantarum OPB15 on pathological changes in colon tissue of model mice
For example 4, clean colon tissue samples were cut with sterile surgical scissors 2 cm, placed in 10% formalin solution for overnight fixation, and then prepared into paraffin sections of colon tissue. Sections were stained with hematoxylin-eosin (HE staining), alisxin blue-periodate schiff stain (AB-PAS staining). The colon histopathological changes were observed under an optical microscope and stored with photographs (fig. 4 and 5).
Fig. 4 HE shows that the model group had the shortest villi and had loose and broken villi, the intestinal wall of the intestinal tissue was significantly thinner than that of the control group, the thickness of the mucus layer was thinner, and the submucosa was damaged; compared with the model group, the intestinal glands of the mice in the positive control group and the mice in the probiotics group are orderly arranged, the structure is basically normal, the thickness of the mucus layer is thickened, and the length of villus is obviously improved. It was shown that lactobacillus plantarum OPB15 can improve colonic tissue morphology, thereby protecting the intestinal tract.
FIG. 5AB-PAS staining shows that goblet cells in the model group were significantly reduced and loosely arranged. The probiotics experiment group and the positive group can restore the goblet cells to a neat state, increase the number of goblet cells and repair damaged colon tissues so as to protect intestinal tracts.
Example 6: therapeutic effect of fermentation product on bacterial vaginosis model mice
Lactobacillus plantarum OPB15 fermentation product group (see example 3). Escherichia coli (ATCC 25922) and Staphylococcus aureus (ATCC 25923) are provided by China food and drug verification institute. The concentration of Escherichia coli and Staphylococcus aureus was 1.0X10 9 cfu/mL of bacterial liquid, and mixing the two bacterial liquids in equal volume. The vagina of the mouse is washed 3 times by PBS solution, a 5-gauge scalp needle silicone tube is smeared with sterile paraffin oil, and the mixture is injected into the vagina of the mouse at about 1.5cm once a day, and each time is 0.05mL/100g. After 5 days of bacterial inoculation, when the vagina of the mouse is engorged with redness and swelling and is accompanied by a large amount of purulent secretion, a large amount of necrotic cells and infectious bacteria can be seen by microscopic observation, and the modeling is successful. The method was used to model all the mice except the normal control group, during which the normal control group mice were flushed with an equal amount of sterile saline 1 time per day. On day 1 after successful molding, the model group is taken out for flora detection, the normal control group is used for flushing vagina with equivalent physiological saline, and the positive control group and the experimental group are treated normally. Wherein the model group does not need treatment, and the flora is directly detected on the 1 st day after the successful modeling.After the positive control group and the experimental group were successfully molded, calculation was started on the 1 st day, and the treatment was continued for 14 days.
SPF-class Balb/c mice are bred in the environment of 40 female animals, the body mass of the female animals is 18-20 g, the temperature is 20-25 ℃, the relative humidity is 50+/-5%, and the illumination time is 12 h/12 h. The animals were randomly divided into 4 groups of 10 animals, and the normal control group, the model group, the positive control group and the experimental group (namely, lactobacillus plantarum OPB15 fermentation product group) were set. (1) Normal control group: washing vagina (0.05 mL/100 g) with physiological saline; (2) model group: washing vagina (0.05 mL/100 g) with physiological saline; (3) positive control group: fuyankang gel treatment (0.01 g/100 g); (4) experimental group: lactobacillus plantarum OPB15 fermentation product spread treatment (0.02 g/100 g); the treatment was continued for 14 days. After 3d withdrawal, each mouse was thoroughly irrigated with sterile PBS, 200. Mu.L of vaginal lavage solution was taken per mouse and collected in sterile tubes. Collecting vaginal lavage fluid of mice, taking partial uterine tissue of the mice, grinding, cracking, homogenizing, centrifuging, taking supernatant, and detecting the levels of IL-6, IL-8 and TNF-alpha of the vaginal lavage fluid according to the operation instructions of IL-6, IL-8 and TNF-alpha assay kit (Nanjing institute of biological engineering). The absorbance (a) of each well at a wavelength of 450 nm was measured using a microplate reader.
As can be seen from Table 4, the number of E.coli and staphylococci in the vagina of the mice was significantly increased (P < 0.05) and the number of lactic acid bacteria was significantly decreased (P < 0.05) compared to the normal group, indicating that the pathogenic bacteria in the vagina increased and the beneficial lactic acid bacteria decreased. Compared with a model group, the fermentation product experimental group and the model group are compared, the number of escherichia coli and staphylococcus of mice treated by the fermentation product is obviously reduced (P is less than 0.05), and the number of lactobacillus is obviously increased (P is less than 0.05), which indicates that after the mice are treated by the fermentation product, the microbial environment in vagina is obviously improved, beneficial bacteria are increased, pathogenic bacteria are reduced, and the number of lactobacillus is obviously increased compared with that of a Fuyankang positive control group. Meanwhile, the data show that the quantity of the lactobacillus in the experimental group is better than that in the normal group, and the vaginal microecological environment balance can be maintained for a long time after treatment.
As shown in Table 5, the levels of inflammatory factors IL-6, IL-8 and TNF- α in vaginal secretions were significantly increased (P < 0.05) in model mice compared to normal control. IL-6, IL-8 and TNF- α levels were 48.12, 44.78 and 72.41, respectively, following dry prognosis of the fermentation product, were close to 45.45, 39.54 and 65.07 levels in the positive control group, with significant reductions in IL-6, IL-8 and TNF- α levels (P < 0.05) compared to the model control group. The fermentation product has the function of obviously reducing the level of inflammatory factors, and has the effect similar to that of the positive control group Fuyankang. The research result shows that the fermentation product can inhibit the synthesis of IL-6, IL-8 and TNF-alpha in the vaginal secretion of mice, thereby relieving the vaginal inflammatory reaction after bacterial infection.
Comparative example 1:
specific embodiment the same as in example 4 was carried out except that Lactobacillus plantarum OPB15 was replaced with Lactobacillus plantarum JYLP-326 (commercially available strain of Jia Yi of well-known, mich. Co., ltd.) and Uric Acid (UA), creatinine (Cr) and urea nitrogen (BUN) levels were measured in serum of hyperuricemia mice.
The results are shown in Table 6, and show that the effects of Lactobacillus plantarum JYLP-326 on Uric Acid (UA), creatinine (Cr) and urea nitrogen (BUN) in serum are 4.35+ -1.03 mg/L, 0.99+ -0.12 mg/L and 20.66+ -1.90 mg/L, respectively, which are significantly higher than those of Lactobacillus plantarum OPB15, 2.87+ -1.09 mg/L, 0.66+ -0.53 mg/L and 15.01+ -0.14 mg/L, respectively. The above data demonstrate that Lactobacillus plantarum has a significant effect on Uric Acid (UA), creatinine (Cr) and urea nitrogen (BUN) levels in serum of hyperuricemia mice and is significantly better than Lactobacillus plantarum JYLP-326.
Comparative example 2
Specific embodiment the same as in example 6 was carried out except that Lactobacillus plantarum OPB15 was replaced with Lactobacillus plantarum JYLP-326 (commercially available strain of Jia Yi of well-known family), and IL-6, IL-8 and TNF- α levels in vaginal secretions of the vaginoses were determined.
The results are shown in Table 7, which shows that the effect of Lactobacillus plantarum JYLP-326 on IL-6, IL-8 and TNF- α levels in vaginal secretions was 59.12.+ -. 1.45pg/mL, 70.30.+ -. 1.53pg/mL and 100.14.+ -. 5.87pg/mL, respectively, significantly higher than 48.12.+ -. 4.01pg/mL, 44.78.+ -. 2.58pg/mL and 72.41.+ -. 5.41pg/mL of Lactobacillus plantarum OPB 15. The above data demonstrate that Lactobacillus plantarum OPB15 has a significant effect on IL-6, IL-8 and TNF- α levels in vaginal secretions of vaginally ill mice, and is significantly better than Lactobacillus plantarum JYLP-326. Lactobacillus plantarum OPB15 has a good effect of relieving vaginal inflammatory response after bacterial infection.
Although embodiments of the present invention have been disclosed for illustrative purposes, those skilled in the art will appreciate that: various substitutions, changes and modifications are possible without departing from the spirit and scope of the invention and the appended claims, and therefore the scope of the invention is not limited to the disclosure of the embodiments.
Claims (7)
1. A lactobacillus plantarum OPB15, characterized in that: the name is as follows: OPB15, class name: lactobacillus plantarum (L.) KummerLactobacillus plantarum) The preservation number is: CGMCC No.27735, date of preservation: 2023, 6, 29, deposit unit: china general microbiological culture Collection center, north Chen Xi Lu No.1, 3, the Korean region of Beijing, and the China general microbiological culture Collection center.
2. Use of a fermentation product of lactobacillus plantarum OPB15 according to claim 1 for the preparation of a cosmetic and/or medical device and/or a disinfectant and/or a medicament capable of restoring the microecological balance in the private parts of women.
3. The use according to claim 2, characterized in that: the medicine, the cosmetic, the medical appliance and the disinfectant have at least one of the following functions:
the micro-ecological balance of the private part is restored, specifically, the number of beneficial bacteria lactobacillus is increased, and the number of pathogenic bacteria escherichia coli and staphylococcus is reduced;
or, restoring the microecological balance of the private parts, in particular, reducing the IL-6, IL-8 and TNF-alpha levels in the vaginal secretion of the mice.
4. Use of lactobacillus plantarum OPB15 according to claim 1 for the manufacture of a medicament for lowering uric acid.
5. The use according to claim 4, characterized in that: the medicament has at least one of the following effects:
reducing uric acid level of mice with hyperuricemia, in particular reducing uric acid, creatinine and urea nitrogen level in serum of the mice, and increasing creatinine and urea nitrogen excretion in urine;
or, reduce hyperuricemia mice uric acid level, recover the length of colon villus of the mice, and improve colon tissue morphology;
or, reducing uric acid level in hyperuricemia mice, restoring damaged colon tissue, and increasing goblet cell number;
wherein the lactobacillus plantarum OPB15 is a living strain, and the activity of the bacterial powder is 1.8X10 10 CFU/g, lavage.
6. The use according to claim 4, characterized in that: the medicament further comprises a pharmaceutically acceptable carrier, which comprises: one or more of a filler, a binder, a disintegrant, and a lubricant.
7. The use according to claim 6, characterized in that: the filler is one or more of microcrystalline cellulose, lactose, mannitol, starch or dextrin; the disintegrating agent is one or more of sodium carboxymethyl starch, crosslinked povidone or low-substituted hydroxypropyl cellulose; the adhesive is one or more of starch paste, syrup, maltose, refined honey or liquid glucose; the lubricant is one or more of magnesium stearate, sodium stearate fumarate, talcum powder or silicon dioxide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311367990.8A CN117106674B (en) | 2023-10-23 | 2023-10-23 | Lactobacillus plantarum OPB15 capable of reducing uric acid and repairing microecological balance of female private parts and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311367990.8A CN117106674B (en) | 2023-10-23 | 2023-10-23 | Lactobacillus plantarum OPB15 capable of reducing uric acid and repairing microecological balance of female private parts and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117106674A CN117106674A (en) | 2023-11-24 |
| CN117106674B true CN117106674B (en) | 2024-03-08 |
Family
ID=88798636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311367990.8A Active CN117106674B (en) | 2023-10-23 | 2023-10-23 | Lactobacillus plantarum OPB15 capable of reducing uric acid and repairing microecological balance of female private parts and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117106674B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111918960A (en) * | 2017-12-05 | 2020-11-10 | 比奥普来克斯有限公司 | Methods and compositions for preventing microbial infections |
| CN115025129A (en) * | 2021-03-05 | 2022-09-09 | 葡萄王生技股份有限公司 | Lactobacillus-containing composition and application thereof in preventing and/or improving skin aging |
| EP4134426A1 (en) * | 2021-08-13 | 2023-02-15 | Symrise AG | Novel bacterial ferment of lactobacillus species |
| CN116024131A (en) * | 2022-12-23 | 2023-04-28 | 深圳保时健生物工程有限公司 | Lactobacillus plantarum strain GOLDGUT-LP101 and application thereof |
| CN116790448A (en) * | 2023-08-21 | 2023-09-22 | 新益(天津)生物科技有限责任公司 | Lactobacillus helveticus OPB102 capable of relieving constipation and diarrhea and application thereof |
| CN116814510A (en) * | 2023-08-29 | 2023-09-29 | 新益(天津)生物科技有限责任公司 | Lactobacillus rhamnosus OPB41 capable of preventing or improving Alzheimer's disease and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9655932B2 (en) * | 2002-03-13 | 2017-05-23 | Kibow Biotech, Inc. | Composition and method for preventing or treating gout or hyperuricemia |
-
2023
- 2023-10-23 CN CN202311367990.8A patent/CN117106674B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111918960A (en) * | 2017-12-05 | 2020-11-10 | 比奥普来克斯有限公司 | Methods and compositions for preventing microbial infections |
| CN115025129A (en) * | 2021-03-05 | 2022-09-09 | 葡萄王生技股份有限公司 | Lactobacillus-containing composition and application thereof in preventing and/or improving skin aging |
| EP4134426A1 (en) * | 2021-08-13 | 2023-02-15 | Symrise AG | Novel bacterial ferment of lactobacillus species |
| CN116024131A (en) * | 2022-12-23 | 2023-04-28 | 深圳保时健生物工程有限公司 | Lactobacillus plantarum strain GOLDGUT-LP101 and application thereof |
| CN116790448A (en) * | 2023-08-21 | 2023-09-22 | 新益(天津)生物科技有限责任公司 | Lactobacillus helveticus OPB102 capable of relieving constipation and diarrhea and application thereof |
| CN116814510A (en) * | 2023-08-29 | 2023-09-29 | 新益(天津)生物科技有限责任公司 | Lactobacillus rhamnosus OPB41 capable of preventing or improving Alzheimer's disease and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117106674A (en) | 2023-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015067141A1 (en) | Lactobacillus crispatus and application thereof | |
| CN114574390B (en) | Bifidobacterium longum subspecies infantis for relieving colonitis and application thereof | |
| CN112458007A (en) | Lactobacillus crispatus for preventing and/or treating diseases related to genital tract flora disorder | |
| CN116790448B (en) | Lactobacillus helveticus OPB102 capable of relieving constipation and diarrhea and application thereof | |
| CN114854638B (en) | Lactobacillus paracasei capable of efficiently expressing adenosine deaminase mRNA to relieve colonitis | |
| CN115895966B (en) | Bifidobacterium bifidum BL002 for assisting in relieving gout and application thereof | |
| CN111518714A (en) | Lactobacillus crispatus capable of preventing and/or treating candida vaginitis | |
| CN115487214A (en) | Application of bacillus coagulans BC99 in relieving diarrhea-predominant irritable bowel syndrome | |
| CN114672436B (en) | Lactobacillus acidophilus and application thereof | |
| CN111387506A (en) | Application of lactobacillus acidophilus and composition containing lactobacillus acidophilus | |
| CN111117925B (en) | Anerostipes sp B2131 bacterium and application thereof in inflammatory bowel disease | |
| CN114107134A (en) | Brevibacillus laterosporus and application thereof | |
| CN115287207B (en) | Application of bifidobacterium lactis TY-S01 in preparation of medicines for preventing or relieving constipation | |
| CN116731929A (en) | Lactobacillus mucilaginosus ZS40 and application thereof | |
| CN113969253B (en) | Bifidobacterium lactis JYBR-390 with constipation treatment effect and application and product thereof | |
| CN108795809B (en) | Product and the application of a kind of lactobacillus plantarum JYLP-002 and its preparation | |
| CN117511811A (en) | Lactobacillus rhamnosus AFY02 for preventing and intervening arthritis and application thereof | |
| CN116970530B (en) | Bifidobacterium breve FPHC4024 for preventing and treating infantile diarrhea and application thereof | |
| CN117106674B (en) | Lactobacillus plantarum OPB15 capable of reducing uric acid and repairing microecological balance of female private parts and application | |
| CN117264814A (en) | Lactobacillus rhamnosus with effects of preventing and treating digestive tract diseases | |
| CN115466699B (en) | Panda-derived lactobacillus salivarius and application thereof in treating or preventing inflammatory bowel diseases | |
| CN113604400B (en) | Novel lactobacillus YUYINGW with diabetes preventing or treating effect | |
| CN113403212B (en) | Intestinal fungus Candida metapsilosis M2006B and application thereof | |
| CN116622593B (en) | Lactobacillus paracasei for fermentation and fermentation process for preparing wind-resistant acid-discharging ferment by same | |
| CN117099850B (en) | Fermented plant-based yoghurt and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |